Price movement over the last 24 hours
ADMA Biologics Inc vs Amplify Cybersecurity ETF — how do they compare? ADMA Biologics Inc trades at $9.21 (market cap $2.13B), while Amplify Cybersecurity ETF trades at $107.5. The key difference: Amplify Cybersecurity ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | HACK | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Sector/Thematic |
52-Week High | $20.38 | $110.27 |
52-Week Low | $7.60 | $70.69 |
Enterprise Value | $2.20B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
HACK trades at $110.27, up 3.08% with strong bullish momentum from moving averages but overbought RSI signals. The cybersecurity ETF benefits from growing sector spending exceeding $300 billion in 2026, with recent partnerships expanding market reach. Technical indicators show strong trend strength while oscillators suggest potential near-term consolidation.
The outlook remains positive given cybersecurity's essential role in AI adoption, though elevated RSI levels indicate near-term overbought conditions. Key risks include sector competition and market volatility, while institutional momentum supports continued growth potential in the expanding cybersecurity market.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.
Read more on HACK →